The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 8, 2011, Pages 2441-2449

  Fitzpatrick, Lorraine A ^a   Dabrowski, Christine E ^a   Cicconetti, Gregory ^a   Gordon, David N ^a   Papapoulos, Socrates ^b   Bone III, Henry G ^c   Bilezikian, John P ^d  

^a GLAXOSMITHKLINE   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Michigan Bone and Mineral Clinic   (United States)

^d New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; BIOCHEMICAL MARKER; CALCITRIOL; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PEPTIDE DERIVATIVE; PLACEBO; PROCOLLAGEN TYPE 1 N PROPEPTIDE; RONACALERET; UNCLASSIFIED DRUG;

ADULT; AGED; ARM FRACTURE; ARTHRALGIA; ARTICLE; BACKACHE; BONE DENSITY; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CALCIUM URINE LEVEL; CONSTIPATION; CONTROLLED STUDY; DENSITOMETRY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSPEPSIA; FEMALE; FEMUR FRACTURE; FEMUR NECK; FEMUR NECK FRACTURE; FOLLOW UP; HEADACHE; HIP; HUMAN; HYPERPARATHYROIDISM; INFLUENZA; LUMBAR SPINE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIUS FRACTURE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VITAMIN BLOOD LEVEL;

ADMINISTRATION, ORAL; AGED; ALENDRONATE; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CALCIUM; FEMALE; HUMANS; INDANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; PATIENT COMPLIANCE; PHENYLPROPIONATES; RECEPTORS, CALCIUM-SENSING; TERIPARATIDE;

EID: 79961216005     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2010-2855     Document Type: Article

References (19)

1. Dobnig H, Turner RT 1997 The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 138:4607-4612 (Pubitemid 27460894)
2. Rubin MR, Bilezikian JP 2003 New anabolic therapies in osteoporosis. Endocrinol Metab Clin North Am 32:285-307 (Pubitemid 36378646)
3. Dempster DW, Müller R, Zhou H, Kohler T, Shane E, Parisien M, Silverberg SJ, Bilezikian JP 2007 Preserved three-dimensional cancellous bone structure in mild primary hyperparathyroidism. Bone 41:19-24 (Pubitemid 46891902)
4. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441 (Pubitemid 32402100)
5. Hodsman AB, Fraher LJ, Watson PH, Ostbye T, Stitt LW, Adachi JD, Taves DH, Drost D 1997 A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 82:620-628 (Pubitemid 27068640)
6. McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF 2005 Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165:1762-1768 (Pubitemid 41138965)
7. Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB; Treatment of Osteoporosis with Parathyroid Hormone Study Group 2007 Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis. Ann Intern Med 146:326-339
8. Kumar S, Matheny CJ, Hoffman SJ, Marquis RW, Schultz M, Liang X, Vasko JA, Stroup GB, Vaden VR, Haley H, Fox J, Del Mar EG, Nemeth EF, Lago AM, Callahan JF, Bhatnagar P, Huffman WF, Gowen M, Yi B, Danoff TM, Fitzpatrick LA 2010 An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation. Bone 46:534-542
9. Fitzpatrick LA, Brennan E, Kumar S, Matheny C, Yi B, McLaughlin M, Phillips J, Skordos L, Ethgen D 2008 Ronacaleret, a novel calcium-sensing receptor antagonist, demonstrates potential as an oral bone-forming therapy in healthy postmenopausal women. Program of the 30th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR), Montreal, Quebec, Canada, 2008 (Abstract S50)
10. Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, Dore RK, Correa-Rotter R, Papaioannou A, Cumming DC, Hodsman AB 2002 A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:4528-4535 (Pubitemid 35247036)
11. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541 (Pubitemid 26411651)
12. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 280:2077-2082 (Pubitemid 29014065)
13. Hodsman AB, Fraher LJ, Ostbye T, Adachi JD, Steer BM 1993 An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. J Clin Invest 91:1138-1148 (Pubitemid 23095292)
14. Silverberg SJ, Shane E, de la Cruz L, Dempster DW, Feldman F, Seldin D, Jacobs TP, Siris ES, Cafferty M, Parisien MV, Lindsay R, Clemens TL, Bilezikian JP 1989 Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 4:283-291 (Pubitemid 19161996)
15. Lindsay R, Nieves J, Henneman E, Shen V, Cosman F 1993 Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1-34): kinetics and biochemical response in estrogenized osteoporotic patients. J Clin Endocrinol Metab 77:1535-1539 (Pubitemid 24000909)
16. Bilezikian JP, Khan AA, Potts Jr JT; Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the third international workshop. J Clin Endocrinol Metab 94:335-339
17. Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, Metcalfe AJ, Lindsay R 2003 Safety and efficacy of human parathyroid hormone (1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 88:5212-5220 (Pubitemid 37452718)
18. Fujita T, Inoue T, Morii H, Morita R, Norimatsu H, Orimo H, Takahashi HE, Yamamoto K, Fukunaga M 1999 Effect of an intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis: a randomized double-masked prospective study using three dose levels. Osteoporosis Int 9:296-306 (Pubitemid 29216763)
19. Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, Siris E, Udesky J, Silverberg SJ 2008 The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 93:3462-3470